Systémová enzymoterapie pro odborníky

Improvement in blood fluidity characteristics via Phlogenzym -An in vitro pilot study

¹Saradeth T., ²QuittanM., ²GhanemA. H., ³ErnstE.

¹University Clinic for Physical Medicine and Rehabilitation Ludwig-Maximilians University, Munich, Germany
²University Clinic for Physical Medicine and Rehabilitation University of Vienna, General Hospital, Austria
³Centre for Complementary Health Studies, Postgraduate Medical School, University of Exeter, United Kingdom

Perfusion 1995: Jahrgang 8, Nr. 6, pp. 196-198.

PZ 4 (17-06-2)

Summary

The goal of this in vitro study was to establish whether Phlogenzym (a mixture of proteolytic enzymes) alters hemorheological variables in the blood of healthy volunteers.
Twelve healthy test subjects with a mean age of 32.1 ± 6.1 years (10 men, 2 women, no smokers) consented to having a single sample of blood taken from a cubital vein. Following anticoagulation with EDTA and the addition of Phlogenzymâ at various doses (18, 36, 71, 107, 214 mg/ml), hematocrit, plasma viscosity, serum viscosity, fibrinogen, native and standardized blood viscosity, erythrocyte aggregation and filterability were measured in vitro. As compared with control blood (with constant hematocrit values), significant reductions in plasma viscosity, the native and standardized blood viscosity (at three different shear rates) and of erythrocyte aggregation were found following even a minimum concentration of 18 ml/ml Phlogenzym®. Erythrocyte filterability was only increased numerically. Aside from the effects on fibrinogen, a 12-fold increase in the concentration of Phlogenzym® (214 ml/ml) demonstrated only insignificant changes and even revealed a slight deterioration in blood fluidity as compared with the control blood (samples without Phlogenzymâ ). These results indicate, at least in part, that there is a dose-dependent increase in the in vitro fluidity of the blood as a result of the activity of the Phlogenzym. These findings will require further investigation via controlled clinical trials.

Keywords: hemorheology, fibrinolysis, volunteers, in vitro study, Phlogenzym


Úvod pro odborníky O firmě Kontakty Pomáháme druhým Poradna
Zánět a jeho ovlivnění SET Zvýšení využitelnosti antibiotik proteolytickými enzymy Angiologie, flebologie Diabetologie Gynekologie Chirurgie, traumatologie, ortopedie Imunologie Lymfologie ORL Pediatrie Revmatologie Sportovní medicína Stomatologie Urologie Literatura Časopisy s Impact faktorem Ostatní literatura SPC Wobenzym SPC Phlogenzym	Improvement in blood fluidity characteristics via Phlogenzym -An in vitro pilot study ¹Saradeth T., ²QuittanM., ²GhanemA. H., ³ErnstE. ¹University Clinic for Physical Medicine and Rehabilitation Ludwig-Maximilians University, Munich, Germany ²University Clinic for Physical Medicine and Rehabilitation University of Vienna, General Hospital, Austria ³Centre for Complementary Health Studies, Postgraduate Medical School, University of Exeter, United Kingdom Perfusion 1995: Jahrgang 8, Nr. 6, pp. 196-198. PZ 4 (17-06-2) Summary The goal of this in vitro study was to establish whether Phlogenzym (a mixture of proteolytic enzymes) alters hemorheological variables in the blood of healthy volunteers. Twelve healthy test subjects with a mean age of 32.1 ± 6.1 years (10 men, 2 women, no smokers) consented to having a single sample of blood taken from a cubital vein. Following anticoagulation with EDTA and the addition of Phlogenzymâ at various doses (18, 36, 71, 107, 214 mg/ml), hematocrit, plasma viscosity, serum viscosity, fibrinogen, native and standardized blood viscosity, erythrocyte aggregation and filterability were measured in vitro. As compared with control blood (with constant hematocrit values), significant reductions in plasma viscosity, the native and standardized blood viscosity (at three different shear rates) and of erythrocyte aggregation were found following even a minimum concentration of 18 ml/ml Phlogenzym®. Erythrocyte filterability was only increased numerically. Aside from the effects on fibrinogen, a 12-fold increase in the concentration of Phlogenzym® (214 ml/ml) demonstrated only insignificant changes and even revealed a slight deterioration in blood fluidity as compared with the control blood (samples without Phlogenzymâ ). These results indicate, at least in part, that there is a dose-dependent increase in the in vitro fluidity of the blood as a result of the activity of the Phlogenzym. These findings will require further investigation via controlled clinical trials. Keywords: hemorheology, fibrinolysis, volunteers, in vitro study, Phlogenzym
	Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci. Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003